Quantcast

Experimental and Clinical Research of Dendritic Cell and Syngeneic Immunotherapy of Brain Glioma

Research paper by Hongquan NIU, Zhen DONG, Fangyong DONG, Tao ZHANG, Ting LEI, Delin XUE

Indexed on: 01 Sep '04Published on: 01 Sep '04Published in: The Chinese-German Journal of Clinical Oncology



Abstract

Objective: To investigate the clinical effect and prospective use of syngeneic brain glioma antigen dendritic cell (DC) vaccine. Methods: DCs were isolated from peripheral blood of brain glioma patients. DCs loaded with different tumor antigens were cocultured with T lymphocytes. The cytotoxity of T lymphocytes to glioma cells was tested by LDH method. Fifty-six glioma patients were divided into 3 groups treated with different methods. Experimental group (19 cases): syngeneic brain glioma antigen DC vaccine and bacilie calmette guerin (BCG); Positive control group (17 cases): glioma homogenate and BCG; Negative control group (20 cases): only radiotherapy after resection. Therapeutic effect of every group was evaluated. Results: High purity DCs could be harvested by GM-CSF and IL-4 culture. The cytotoxicity of DC was enhanced when loaded with tumor antigen. There were different therapeutic effects among 3 groups. The median survival time in group 1 (38 months) and group 2 (24 months) was significantly longer than that in group 3 (13 months). Conclusion: Syngeneic brain glioma antigen DC vaccine could inhibit the recurrence and progression of glioma. This method can prolong the survival time of brain glioma patients.